Skip to main content
Clinical Trials/NCT03452410
NCT03452410CompletedNot Applicable

Positive Diagnosis of Vestibular Neuritis Using Fluid Attenuated Inversion Recuperation (FLAIR) Sequence, One Hour After Intravenous Gadolinium Injection, on a 1.5 Tesla

University Hospital, Strasbourg, France1 site in 1 country35 target enrollmentStarted: February 23, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
35
Locations
1
Primary Endpoint
Diagnosis of vestibular neuritis

Study Overview

Brief Summary

Our objective is to allow positive MRI diagnosis of vestibular neuritis by highlighting contrast enhancement of the vestibular nerve on the pathological side of the FLAIR sequence acquired 1h after intravenous gadolinium injection in patients with typical vestibular neuritis. At present, the diagnosis is based on a combination clinical examination / video-head impulse test, and no imaging examination allows the diagnosis to be positive.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18-80 years
  • Presence of a typical unilateral vestibular neuritis during the ENT examination with videonystagmography
  • Subject having his agreement for the use of his medical data for research purposes.

Exclusion Criteria

  • Special clinical forms of the disease: doubtful or atypical forms, especially the presence of deafness
  • Treatments and related interfering diseases, antecedents: antecedents of neuritis for controls, presence of vertigo, bilateral involvement
  • Impossibility to give the subject information enlightened (subject in emergency situation, difficulties of understanding the subject, ...)
  • Subject under the protection of justice
  • Subject under guardianship or curatorship

Outcomes

Primary Outcomes

Diagnosis of vestibular neuritis

Time Frame: one hour after intravenous gadolinium injection

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University Hospital, Strasbourg, France
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials